Activation of TLR9 signaling can also be achieved by synthetic oligonucleotides and hold strong potential for treating cancer several such compounds are in clinical testing. It is activated by DNA that contains motifs, which are frequently present in bacterial DNA. TLR9 signaling is an important innate immune pathway that is relevant as a first-line defense mechanism against pathogens. The publication describes the preclinical activity of Secarna's high-affinity bimodal LNAplus™-based ASO, IM-T9P1, that simultaneously triggers toll-like receptor 9 (TLR9) signaling and downregulates programmed cell death ligand 1 (PD-L1) expression, a protein involved in the suppression of the adaptive immune system, in one molecular entity. Mikael Pittet, Department of Pathology and Immunology, University of Geneva and Secarna and can be found here. Alfred Zippelius, Department of Biomedicine, Basel University Prof. The article, "Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity," discusses the joint work of the teams of Prof. The data were published in the peer-reviewed publication, Journal for ImmunoTherapy of Cancer.
KG ("Secarna"), a biopharmaceutical company focusing on the discovery and development of next-generation antisense oligonucleotide (ASO) therapies to address challenging or previously undruggable targets via its LNAplus™ platform, announced the publication of striking new preclinical data demonstrating that bimodal ASOs can enable efficacious long-term antitumor immunity in tumor models compared to current immune checkpoint inhibitors. MUNICH and MARTINSRIED, GERMANY / ACCESSWIRE / J/ Secarna Pharmaceuticals GmbH & Co. Combination of both activities in a single-molecule approach results in exceptional anti- tumor activity in different tumor models.Secarna's LNAplus™-based ASOs effectively stimulate TLR9 signaling, an important innate immune pathway, and simultaneously suppress PD-L1 expression, a clinically validated immune checkpoint.Compelling in vivo and in vitro data published in peer-reviewed Journal for ImmunoTherapy of Cancer (JITC).
0 kommentar(er)
